Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market: Key Factor Driving The Growth In The GLP-1 Receptor Agonist Market

The GLP-1 Receptor Agonist Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current GLP-1 Receptor Agonist Market Size and Its Estimated Growth Rate?
The market for GLP-1 receptor agonist has seen consistent expansion in the past few years. It is projected to increase from $13.58 billion in 2024 to $14.22 billion in 2025, boasting a compound annual growth rate (CAGR) of 4.7%. Factors such as the increasing prevalence of diabetes, clinical effectiveness, patient consciousness and consent, global health campaigns, and a preference among patients for injectable treatments have been instrumental in the growth during the historic period.

The market for GLP-1 receptor agonist is predicted to witness robust growth in the upcoming years, expanding to a value of $17.72 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 5.7%. Factors contributing to this growth within the anticipated time frame include an increased focus on managing lifestyle, emerging trends in personalized medicine, broader indications, the advent of next-generation products, and their incorporation in combined therapies. Key trends expected during this period feature the launch of oral formulations, emphasis on combined therapies, strategic alliances and partnerships, patient-oriented approaches, and policies surrounding reimbursement and access.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9631

What Are the High-Growth Segments in the GLP-1 Receptor Agonist Market?
The GLP-1 receptor agonist market covered in this report is segmented -

1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users

Subsegments:
1) By Exenatide: Byetta, Bydureon
2) By Liraglutide: Victoza, Saxenda
3) By Dulaglutide: Trulicity
4) By Lixisenatide: Adlyxin
5) By Other Drugs: Semaglutide, Tirzepatide, Others

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9631&type=smp

What Key Drivers Are Expected to Influence Future GLP-1 Receptor Agonist Market Growth?
The escalating incidences of diabetes are projected to stimulate the GLP-1 receptor agonist market's growth. Diabetes, a long-term disease, occurs when the pancreas fails to generate adequate insulin or when the body cannot effectively use the insulin it does produce. Elevated blood sugar levels signify the metabolic disease known as diabetes mellitus. The application of GLP-1 receptor agonist in diabetes stimulates the body to generate additional insulin, thereby reducing blood sugar levels. That is why anticipated growth in diabetes cases will fuel the market expansion. For example, in March 2024, the UK's governmental department, the Office for Health Improvement and Disparities, reported that from March 2022 to March 2023, the proportion of individuals receiving all eight suggested care procedures for type 1 diabetes surged by 22%, and for type 2 diabetes, it increased by 21%. Simultaneously, the percentage reaching the desired HbA1c levels spiked to 37.9%, marking the highest value ever recorded by the National Diabetes Audit (NDA). Hence, the proliferating occurrence of diabetes is spurring the GLP-1 receptor agonist market.

Which Companies Hold the Largest Share Across Different GLP-1 Receptor Agonist Market Segments?
Major companies operating in the GLP-1 receptor agonist market include Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG

What Trends Are Driving Growth in The GLP-1 Receptor Agonist Market?
Innovations in products are emerging as a critical trend in the GLP-1 receptor agonist market. To bolster their stance, the leading corporations in the GLP-1 receptor agonist market are centering their efforts on developing ingenious solutions. In May 2022, for instance, Eli Lilly and Company, a US-based pharmaceutical firm committed to improving lives through their medicines, released Mounjaro, an FDA-approved GLP-1 and GIP receptor agonist. Mounjaro has been distinctly constructed with a lone molecule that triggers the human body's GIP and GLP-1 incretin hormone receptors. Available as an auto-injector pen, it features a concealed, pre-installed needle that patients do not have to manage or view, and it is available in 6 different dosages.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/glp-1-receptor-agonist-global-market-report

What Are the Emerging Geographies for The GLP-1 Receptor Agonist Market Growth?
North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the GLP-1 Receptor Agonist Market?
2. What is the CAGR expected in the GLP-1 Receptor Agonist Market?
3. What Are the Key Innovations Transforming the GLP-1 Receptor Agonist Industry?
4. Which Region Is Leading the GLP-1 Receptor Agonist Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.